Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $24.40.

Several equities research analysts have recently commented on ANRO shares. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Robert W. Baird dropped their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd.

Alto Neuroscience Price Performance

ANRO stock opened at $4.22 on Thursday. The business has a fifty day moving average price of $11.90 and a 200 day moving average price of $12.26. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience has a fifty-two week low of $3.93 and a fifty-two week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. On average, analysts anticipate that Alto Neuroscience will post -2.63 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Large investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in shares of Alto Neuroscience in the first quarter valued at about $21,267,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience in the 1st quarter valued at approximately $9,788,000. Vanguard Group Inc. acquired a new position in Alto Neuroscience during the 1st quarter worth approximately $8,233,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the 1st quarter worth approximately $7,039,000. Finally, Artal Group S.A. acquired a new stake in shares of Alto Neuroscience in the first quarter valued at approximately $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.